Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· LongevityAudio: English

Brain Training and Dementia Risk: What the 10-Year ACTIVE Trial Found

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

In the ACTIVE randomized trial of 2,802 initially healthy older adults, speed-of-processing training was associated with a hazard ratio of 0.71 for dementia over ten years, while memory and reasoning training were not. The confidence interval for speed training ran from 0.50 to 0.998, so the result is borderline. This video explains what was tested, why it is interesting, and why commercial brain games are a different question. Brain training is a multi-billion-dollar idea built on a hopeful premise: practice the right mental exercises and you can protect your thinking as you age. Most of that market has rested on thin evidence. But one trial is different. It is called ACTIVE, it enrolled more than two thousand older adults, and it followed them for ten years. In a 2017 analysis, participants randomized to a specific type of cognitive training, speed-of-processing training, had a hazard ratio of zero point seven one for dementia, compared with a no-contact control group. Memory training and reasoning training did not --- Paper cited: Speed of processing training results in lower risk of dementia Authors: Edwards JD, Xu H, Clark DO, Guey LT, Ross LA, Unverzagt FW Journal: Alzheimer's & Dementia: Translational Research & Clinical Interventions Year: 2017 DOI: 10.1016/j.trci.2017.09.002 --- Subscribe for one peer-reviewed paper made practical, every Tuesday and Friday. Free guide: How to Read Your Biomarker Panel at 55+ - {{LEAD_MAGNET_URL}} --- EDUCATIONAL CONTENT - NOT MEDICAL ADVICE This video is for general educational and informational purposes only. It summarizes peer-reviewed research. It does NOT constitute: - Medical advice, diagnosis, or treatment - Recommendations to start, stop, or change any medication - Dosing instructions for supplements or interventions - A substitute for consultation with a licensed physician Before applying anything discussed: - Talk to your physician, especially if you take prescription medications (statins, metformin, blood thinners, antihypertensives, GLP-1 agonists, etc.) - Discuss interactions, contraindications, and your individual risk profile - Get baseline biomarkers before changing your regimen if relevant Specific cautions: - Intermittent fasting: not appropriate for people with diabetes (especially Type 1), history of eating disorders, pregnancy, or underweight status without medical supervision. - Strength/Zone-2 training: medical clearance recommended for cardiovascular or joint conditions before initiating new training loads. - Supplements: third-party tested products preferred; verify drug interactions. AFFILIATE DISCLOSURE (FTC compliant): Some links in the description may be affiliate links. We may earn a commission at no additional cost to you. We only feature products and tools relevant to the research discussed. AI-ASSISTED PRODUCTION: Voice narration is generated via Edge TTS (Microsoft Neural Voice). Research, scriptwriting, and review are conducted by a human editor before publication. Reviewed: 2026-10-12

Longevity · 14 min · Source published: 2026-10-13

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…